CHICAGO, August 31, 2026
GE HealthCare announced that its Photonova™ Spectra photon-counting computed tomography (PCCT) system has received CE Mark, expanding the availability of the advanced imaging technology across Europe and other CE Mark-observing markets. The regulatory milestone follows the system’s U.S. FDA 510(k) clearance and Japanese regulatory approval earlier in 2026, strengthening the company’s international rollout of photon-counting CT technology. Photonova Spectra is powered by GE HealthCare’s proprietary Deep Silicon™ detector technology, which is designed to deliver ultra-high-definition imaging, spectral information and wide detector coverage while supporting faster image acquisition and streamlined CT workflows. The company said the CE Mark enables it to begin commercial activities in countries that observe the designation.
Deep Silicon Technology Drives Advanced CT Imaging
GE HealthCare said Photonova Spectra was engineered around its Deep Silicon detector technology, which enables the system to capture detailed spectral information during every scan. The platform combines ultra-high-definition imaging, on-demand spectral and spatial imaging, and wide detector coverage, with the goal of helping clinicians visualize subtle tissue variations, small lesions and vascular structures. The system provides 80 mm detector coverage and a reported 0.23-second rotation speed, supporting rapid acquisitions across different clinical applications. GE HealthCare also designed Photonova Spectra around a one-protocol approach intended to simplify examinations by allowing clinicians to access spectral and ultra-high-definition reconstructions without requiring separate scan protocols. The company said these capabilities are intended to support disease detection, characterization and treatment monitoring, while reducing workflow complexity for imaging teams.
LungFit GO Builds on Home Nitric Oxide Data
The Photonova Spectra platform is designed for use across several areas of clinical imaging, including neurology, oncology, musculoskeletal imaging, thoracic imaging and cardiology. In neurology, the system is designed to visualize small anatomical structures and distinguish brain grey and white matter. In oncology, spectral imaging and iodine mapping are intended to support lesion characterization and treatment monitoring. For musculoskeletal applications, ultra-high-definition imaging is designed to help visualize small fractures and bone marrow changes, while thoracic imaging focuses on detailed visualization of chest structures. In cardiology, the combination of spectral imaging, high-definition imaging and wide detector coverage is intended to support applications such as in-stent lumen assessment, plaque characterization and myocardial imaging. GE HealthCare also sees potential research applications in quantitative imaging, tissue characterization and spectral biomarker discovery, as the technology provides richer imaging datasets than conventional CT approaches.
Advertisement
GE HealthCare Expands European Clinical Collaboration
GE HealthCare is also advancing clinical evaluation of Photonova Spectra through collaborations with UZ Brussel – Vrije Universiteit Brussel in Belgium and Rigshospitalet in Denmark. The collaborations are focused on evaluating photon-counting CT across clinical areas including cardiology, oncology, neurology and musculoskeletal imaging, while exploring applications such as low-dose imaging, tissue characterization and spectral imaging. Photonova Spectra is designed to handle the substantial data volumes generated by photon-counting CT, with GE HealthCare stating that the system can manage up to 50 times more data than conventional CT through NVIDIA accelerated computing and CUDA-optimized reconstruction. With the CE Mark now secured, GE HealthCare is positioned to expand access to Photonova Spectra across European markets, supporting the company’s broader strategy to advance high-definition, spectral and data-intensive medical imaging technologies.
Source: GE HealthCare press relese
